Home » FDA Pilots Risk-Benefit Framework in Six NME Applications
FDA Pilots Risk-Benefit Framework in Six NME Applications
The FDA is using a decisionmaking matrix to weigh expected clinical benefits for biopharmaceuticals against their risks in a pilot program using six NME applications under review.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May